Cancer The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing. Feb 1, 2023 Novartis' Oncology Drugs See Solid Growth in Q4 2022 Premium Feb 1, 2023 Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Feb 1, 2023 Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Feb 1, 2023 Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Jan 31, 2023 Pfizer Q4 Oncology Revenues Fall 7 Percent Premium Jan 31, 2023 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers Jan 31, 2023 Aptose Biosciences Begins Expansion Trial of Tuspetinib in TP53, FLT3-Mutant AML Jan 31, 2023 International Commission to Expand Molecular Testing Access for Cancer Patients Jan 31, 2023 NYU Langone Perlmutter Cancer Center to Validate Biological Dynamics Pancreatic Cancer Test Jan 31, 2023 Guardant Health to Integrate Lunit's AI PD-L1 Scoring Algorithm Into Tissue Test Offering Jan 31, 2023 Arima Genomics to Offer NGS-Based Gene Fusion Test Through Protean BioDiagnostics CLIA Lab Jan 30, 2023 C4 Therapeutics Begins Phase I/II Trial of Protein Degrader in BRAF V600-Mutant Solid Tumors Jan 30, 2023 Daiichi Sankyo, AstraZeneca Begin Phase III Trial of TROP2 Inhibitor, Keytruda in NSCLC Jan 30, 2023 Menarini's Orserdu, Guardant's ctDNA CDx Net FDA Approval for ESR1-Mutated Breast Cancer Patients Jan 27, 2023 Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Jan 27, 2023 Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial Jan 27, 2023 In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck Jan 26, 2023 Circulating Tumor DNA Testing Informs Best Second-Line Treatment for Gastrointestinal Stromal Tumors Premium Jan 26, 2023 NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients Jan 26, 2023 BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers What's Popular? In Cancer Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology International Commission to Expand Molecular Testing Access for Cancer Patients Guardant Health to Integrate Lunit's AI PD-L1 Scoring Algorithm Into Tissue Test Offering Novartis' Oncology Drugs See Solid Growth in Q4 2022 Premium Amgen's Lumakras Sales Increased 58 Percent in Q4 2022